title: Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea.
abstract: BACKGROUND
  Systemic antibiotics such as tetracycline are well accepted as effective in treating the inflammatory papular/pustular phase of rosacea but may be associated with systemic side-effects. Few controlled data on the use of topical antibiotics in rosacea are available.
  
  
  OBJECTIVE
  We evaluated the efficacy and tolerability of a fixed combination of 5% benzoyl peroxide and 1% clindamycin in a topical gel for the treatment of rosacea. Methods This was a 12-week, double-blind, vehicle-controlled, randomized, prospective, parallel-group study in 53 patients with moderate to severe rosacea.
  
  
  RESULTS
  The mean percentage reduction in papules and pustules from baseline to the end of treatment was 71.3% in the benzoyl peroxide/clindamycin group (n = 26) and 19.3% in the vehicle group (n = 26; P = 0.0056). A significant (P = 0.0141) difference in favor of benzoyl peroxide/clindamycin was evident by the third week of treatment. Severity scores for erythema, papules/pustules, and flushing/blushing decreased more with benzoyl peroxide/clindamycin than with vehicle. Overall rosacea severity, Physician Global Assessment, and Patient's Global Assessment at the end of treatment were all significantly improved with benzoyl peroxide/clindamycin compared with vehicle (P = 0.0101, 0.0026, and 0.0002, respectively). Application site reactions were reported in four patients (14.8%) in the benzoyl peroxide/clindamycin group.
  
  
  CONCLUSIONS
  A once-daily topical application of a combination of 5% benzoyl peroxide and 1% clindamycin is effective and well tolerated in patients with moderate to severe rosacea.
authors.affiliation: University Dermatology Consultants, Cincinnati, OH, USA. bergevr@ucmail.uc.edu
authors.forename: Debra
authors.initials: D
authors.lastname: Breneman
authors.forename: Ronald
authors.initials: R
authors.lastname: Savin
authors.forename: Christine
authors.initials: C
authors.lastname: VandePol
authors.forename: George
authors.initials: G
authors.lastname: Vamvakias
authors.forename: Sharon
authors.initials: S
authors.lastname: Levy
authors.forename: James
authors.initials: J
authors.lastname: Leyden
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001585:Benzoyl Peroxide / Q000008:administration & dosage*; D002981:Clindamycin / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005782:Gels; D049670:History, 17th Century; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012393:Rosacea / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents; D005782:Gels; D002981:Clindamycin; D001585:Benzoyl Peroxide